Goldman Sachs Downgrades Apellis to Sell
Goldman Sachs cut Apellis stock to "Sell," lowering the price target to $18. Risks include slow near-term growth and lower Syfovre sales.
/ 1680 items
#XY↓
Evaxion Secures Landmark AI-Discovered Vaccine Deal with MSD
Evaxion secured a major licensing deal for its AI-discovered vaccine, EVX-B3, with Merck & Co. (MSD), potentially worth over $600 million and validating Evaxion's groundbreaking AI platform.
Capricor's HOPE-3 Trial: Clear Path Ahead for DMD Treatment
Capricor's DMD drug (HOPE-3 trial) got key FDA alignment, speeding up the approval process using existing files. Data is expected mid-Q4, with potential approval by mid-2026. Shares jumped 9%.
PSTV's CNSide Now Available to UnitedHealthcare Members for Advanced Cancer Testing
A new agreement lets 51 million UnitedHealthcare members access the CNSide test starting 9/2025. This specialized test accurately finds cancer cells that have spread to the brain and spinal cord lining (leptomeningeal metastases), helping doctors choose the best treatment.
PepGen Shares Double after Muscle Disease Drug Shows Promise in Trial
PepGen's DM1 drug (PGN-EDODM1) showed a record 53.7% splicing correction following a single dose. Experts expect this fix to lead to functional benefits for patients. A minor, reversible kidney issue was noted in one patient.
Immuneering Atebimetinib Demonstrates Exceptional Pancreatic Cancer Survival
New pancreatic cancer drug (atebimetinib + chemo) shows "extraordinary" results: 86% overall survival (OS) at 9 months, far exceeding the 47% standard of care. Pivotal trials planned for late 2025.